Fiona Simpkins, M.D.

faculty photo
Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Department: Obstetrics and Gynecology

Contact information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
Education:
B.S (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
(Molecular Signaling Section, Cancer Research Training Fellowship)
NIH, NCI, 2005.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

*Simpkins F, Jang K, Yoon H, Hew K, Kim M, Azzam D, Sun J, Zhao D, Ince, T, Liu W, Guo W, Zhi Wei, Zhang G, Mills G, *Slingerland JM: *Co-corresponding authors. Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells. Clin Cancer Res June 2018.

Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach RH, Lin LL: A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. J Clin Invest May 2018.

George E, Kim H, Ragland R, Butler L, Morgan M, Gilad O, Brown E, Simpkins F: Improving the efficacy of PARP inhibition with a novel ATR inhibitor, ATRN119, in ovarian high grade serous cancers (HGSC). Poster presented at: Society of Gynecologic Oncology, New Orleans, LA, Mar 2018.

Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R: BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Cell Rep 21(12):3398-3405, Dec 2017.

Garcia-Soto AE, Schreiber T, Strbo N, Ganjei-Azar P, Miao F, Koru-Sengul T, Simpkins F, Nieves-Neira W, Lucci J 3rd, Podack ER: Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors. Gynecol Oncol 145(3):413-419, Jun 2017.

Kim H, George E, Ragland RL, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown EJ, Simpkins F: Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models. Clin Cancer Res 23(12):3097-3108, Jun 2017.

Jang K, Kim M, Gilbert CA, Simpkins F, Ince TA, Slingerland JM: VEGFA activates an epigenetic pathway upregulating ovarian cancer-initiating cells. EMBO Mol Med 9(3):304-318, Mar 2017.

George E, Simpkins F, Ragland R, Rafail S, R Zhang, Morgan MA, Herlyn M, Brown E: Targeting the TR-Chk1 axis with PARP inhibition results in tumor regression in BRCA mutant models. Poster presented at: Society of Gynecologic Oncology, National Harbor, MD, Mar 2017.

Rose PG, Ali S, Moslemi-Kebria M, Simpkins F: Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma. Int J Gynecol Cancer 27(3):452-458, Mar 2017.

Chen J, Solomides C, Simpkins F, Simpkins H: The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy. Cancer Chemother Pharmacol 79(2):369-380, Feb 2017.

back to top
Last updated: 08/01/2018
The Trustees of the University of Pennsylvania